Successful recruitment of monolingual Spanish speaking Latinos to university phase II and III outpatient COVID-19 clinical treatment trials in Northern CaliforniaClinical Trial Published on 2022-09-012022-10-05 Journal: Contemporary clinical trials [Category] 유전자 메커니즘, 임상, 진단, 치료법, [키워드] authorization Clinical treatment clinical trial contribute COVID-19 Emergency Enrollment EUA FDA Health Latino Mild Moderate COVID-19 monoclonal antibody Outpatient patients Population receive recruited recruitment research coordinator Spanish Stanford University Treatment treatment trial Trial with COVID-19 [DOI] 10.1016/j.cct.2022.106891 [Article Type] Clinical Trial
Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trialRandomized Controlled Trial Published on 2022-08-262022-10-05 Journal: Trials [Category] SARS, 임상, [키워드] acute respiratory syndrome adverse event adverse events age antiparasitic drug assigned caused coronavirus coronavirus disease COVID-19 double-blind duration of hospitalization Effectiveness Efficacy enrolment Frequency group hospitalized patient Ivermectin ivermectin treatment Mild Moderate COVID-19 n=36 negativity no difference outbreak overcome pandemic Patient PCR-positive PCR-positive patient Placebo placebo-controlled placebo-controlled trial polymerase chain Primary outcome proportion Randomized Randomized controlled trial Randomly receiving reported reverse transcription RT-PCR SARS-CoV-2 Secondary endpoints secondary outcome shown Side effects significant difference single-center standard care Standard of care survival symptomatic Symptoms therapeutic Treatment Trial worsening [DOI] 10.1186/s13063-022-06649-3 PMC 바로가기 [Article Type] Randomized Controlled Trial
Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agentsReview article Published on 2022-08-262022-10-05 Journal: The Lancet. Infectious Diseases [Category] SARS, 임상, 치료법, 치료제, [키워드] anti-inflammatory agent Anti-inflammatory drugs Care caused complications COVID-19 COVID-19 symptoms disease symptom excessive inflammatory response home inhibitors initial management Mild Moderate COVID-19 non-steroidal anti-inflammatory drug NSAID NSAIDS observational study Prevent progression protocols SARS-CoV-2 selective Stage Symptom symptom severity tested the disease therapeutic strategy Treatment viral infection [DOI] 10.1016/S1473-3099(22)00433-9 [Article Type] Review article
The efficacy of combined therapy of qingfeiPaidu capsule and lianhuaqingwen capsule nursing interventions for hospitalized patients with COVID-19: A retrospective study of medical recordsRandomized Controlled Trial Published on 2022-08-122022-10-04 Journal: Medicine [Category] 임상, [키워드] affecting alleviate anti-inflammatory effect baseline Blood Blood urea nitrogen C-reactive protein caused Chinese circulating Clinical characteristics clinical symptom Clinical symptoms Combined Combined therapy COVID-19 COVID-19 patient criteria demonstrated discharge Efficacy enrolled global pandemic group groups Hospitalization hospitalized patient immune function individuals Inflammation Intervention Laboratory lactate dehydrogenase life-threatening lung Lymphocyte count medical record Medicine Mild Moderate COVID-19 outcome outcomes Patient patients with COVID-19 Prognosis pulmonary inflammation Randomly Retrospective study severity scores therapy Traditional Treatment were recorded White blood cells [DOI] 10.1097/MD.0000000000029964 PMC 바로가기 [Article Type] Randomized Controlled Trial
Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trialRandomized Controlled Trial Published on 2022-08-042022-10-04 Journal: PLoS ONE [Category] SARS, 임상, [키워드] 95% CI adverse event assigned contrary COVID-19 defined died Efficacy enrolled extracorporeal membrane oxygenation Follow-up Hypothesis IMPROVE inhibitor intravenous mechanical ventilation Moderate COVID-19 monitoring board occurred Odds ratio Open-label outcome overall survival oxygen Patient patients patients with COVID-19 patients with moderate Pneumonia presenting Primary outcome proportion Randomized controlled trial randomly assigned patient receive respiratory symptom risk significantly lower Standard of care Treatment Trial with COVID-19 [DOI] 10.1371/journal.pone.0269065 PMC 바로가기 [Article Type] Randomized Controlled Trial
The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trialRandomized Controlled Trial Published on 2022-08-012022-10-05 Journal: Contemporary clinical trials [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] 95% CI adjusted odds ratio age Analysis antibody authorization Bayesian COVID-19 criteria death decrease defined Effectiveness Emergency enrolled equivalence funding Government Health health system Hospitalization inferiority IQR Local mAb median Mild moderate Moderate COVID-19 monoclonal neutralize Odds ratio outcome Patient Placebo Platform trial posterior probability Probability provided random randomized clinical trial Registered relative reported SARS-CoV-2 Sex statistical Treatment Trial [DOI] 10.1016/j.cct.2022.106822 PMC 바로가기 [Article Type] Randomized Controlled Trial
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trialCOVID-19 회복기 참가자에 대한 FINLAY-FR-1A 백신의 안전성 및 면역원성: 공개 라벨 2a상 및 이중 맹검, 무작위 배정, 위약 대조, 2b상, 심리스, 임상 시험Clinical Trial Published on 2022-08-012022-09-11 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] 95% CI adverse event All participants Alpha anti-RBD antibody assigned Asymptomatic Beta clinical clinical trial clinical trials Complete control group control groups convalescent convalescent individual convalescent individuals COVID-19 criteria Cuba defined delta variant Delta variants dimeric double-blind education elicited ELISA Endpoint enrolled Environment evaluate evaluated experimental group first stage geometric mean geometric mean titre geometric mean titres greater hematology ICTRP IgG antibodies immune response immunogenicity immunology increase in injected injection injection site Intervention intervention group Mild minor Moderate COVID-19 natural immunity Negative PCR neutralisation test neutralising antibody Occurrence Open-label Pain participant Participants PCR test per-protocol population Phase 1 Phase 2 Placebo placebo group placebo-controlled prevaccination Primary outcome Primary outcomes Public randomised Randomly Receptor binding domain recruited Registered registry reported Safety safety analysis safety population safety profile SARS-CoV-2 Science seamless secondary Secondary endpoints Serious Adverse Event Serious Adverse Events seroconversion rate sexual single dose stages study population technology the placebo group titre Trial two groups vaccination Vaccine vaccine immunogenicity Virus neutralisation Volunteer was done WHO-ICTRP [DOI] 10.1016/S2213-2600(22)00100-X PMC 바로가기 [Article Type] Clinical Trial
ESCMID COVID-19 guidelines: update on treatment for patients with mild/moderate diseaseMini review Published on 2022-08-012022-10-05 Journal: Clinical microbiology and infection : the official [Category] 임상, 치료법, 치료제, [키워드] addressed administration Antiviral antivirals approach circulating variant Committee coronavirus disease COVID-19 COVID-19 guideline death disease Disease progression epidemiological Europe healthcare Hospitalization Intervention involved mAb mAbs majority mandatory Mild Moderate COVID-19 monoclonal antibody omicron other treatment outcome Outpatient Patient performed PICO Prevent Protein question recommendation Remdesivir risk SARS-CoV-2 selected spike Treatment Vaccine variant variants of concern was used while [DOI] 10.1016/j.cmi.2022.08.013 [Article Type] Mini review
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19 : A Randomized, Placebo-Controlled Trial코로나19의 바이오마커, 호흡기 중재 및 의료 서비스에 대한 몰누피라비르의 효과 : 무작위, 위약 대조 시험Randomized Controlled Trial Published on 2022-08-012022-09-11 Journal: Annals of internal medicine [Category] COVID19(2023년), MERS, SARS, 바이오마커, 임상, [키워드] 95% CI Analysis assigned baseline benefit C-reactive protein C-reactive protein (CRP Care change clinical benefit clinically Concentration COVID-19 CRP death discharge discharged double-blind Effect evaluated faster Hospitalization Hospitalized identify immunized improvement Improvements Inc Invasive mechanical ventilation less LLC median medical service medical services Mild mild to moderate Mild to moderate COVID-19 Moderate COVID-19 molnupiravir Older oxygen oxygen saturation participant performed Phase 3 Placebo placebo-controlled placebo-treated participant placebo-treated participants potential clinical benefit progression randomization Randomized Randomly receiving reduction in Relative risk respiratory respiratory intervention respiratory interventions risk risk factor Risk factors risk reduction SARS-CoV-2 secondary service severe disease Sharp subsidiary therapy Trial [DOI] 10.7326/M22-0729 PMC 바로가기 [Article Type] Randomized Controlled Trial
Increased plasma level of soluble P-selectin in non-hospitalized COVID-19 convalescent donors입원하지 않은 COVID-19 회복기 기증자에서 가용성 P-셀렉틴의 혈장 수준 증가Article Published on 2022-08-012022-09-11 Journal: Thrombosis research [Category] MERS, 바이오마커, 임상, [키워드] Activation acute disease baseline characteristics Biomarker Blood blood donor Blood donors blood sampling CD62P Characteristics Coagulation Coagulation system comparable Control controls convalescent coronavirus coronavirus disease coronavirus disease-2019 COVID-19 COVID-19 convalescent donor COVID-19 convalescent donors COVID-19 diagnosis COVID-19 symptom COVID-19 symptoms decrease demonstrated disease disease severity Donor donors ELISA endothelial evaluated Factor flow cytometry hospitalized COVID-19 patient hospitalized COVID-19 patients implication in vitro Increased lead longitudinal study marker Moderate COVID-19 MOST non-infected P-selectin Participation phenotype plasma plasma concentration Plasma marker plasma samples Platelet platelet activation Platelet function procoagulant questionnaire recruited reported Research SARS-CoV-2 SARS-COV-2 infection significantly higher Soluble P-selectin. study groups suffered systemic disease Transmission Trial Vascular was determined was measured was obtained was performed were recorded [DOI] 10.1016/j.thromres.2022.06.014 PMC 바로가기 [Article Type] Article